Precigen Inc. (PGEN)
PGEN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$7.48
-2.35% on the day
Market cap
$2.7B
Mid cap
Revenue · 2025
$9.7M
+146.7% on 2024
Net income · 2025
-$250.6M
-2587.8% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | PGEN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001356090 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | VA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $9.7M |
| Net income | -$250.6M |
| Operating income | -$110.5M |
| Net margin | -2587.8% |
| Operating margin | -1141.1% |
| Revenue growth | +146.7% |
| Cash | $30.2M |
| Total assets | $155.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 276.5× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3 | S-3 | 2025-08-19 |
| Latest annual report | 10-K | 2026-03-25 |
| Latest quarterly / interim | 10-Q | 2026-08-04 |
| Latest current report FORM 8-K | 8-K | 2026-08-04 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.2% |
| 1 month | +5.4% |
| 3 months | +49.0% |
| Year to date | +76.4% |
| 1 year | +129.8% |
| From 52-week high | -13.8% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ZLAB | Zai Lab Limited | $23.10 | -6.06% | $2.6B |
| VCRE | Vicore Pharma Holding AB | $8.95 | -3.03% | $2.5B |
| DYN | Dyne Therapeutics Inc. | $15.30 | -4.13% | $2.9B |
| SLS | SELLAS Life Sciences Group Inc. | $12.41 | +4.02% | $2.5B |
| RCUS | Arcus Biosciences Inc. | $22.51 | -7.52% | $2.9B |
| ELVN | Enliven Therapeutics Inc. | $39.49 | -3.31% | $2.9B |
| SUPN | Supernus Pharmaceuticals Inc. | $42.01 | -1.87% | $2.4B |
| NAMS | NewAmsterdam Pharma Company N.V. | $20.19 | -4.99% | $2.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier